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ABSTRACT 
Accurate diagnosis of malignant pleura mesothelioma (MPM) is challenging. Differential di-
agnosis of MPM versus lung adenocarcinoma (AD) is particularly difficult, yet clinically im-
portant since the two neoplasias call for different treatment approaches. Circulating miRNA-
profiling to identify miRNAs that can be used to distinguish MPM from AD has not been re-
ported.  
We conducted a wide screening study of miRNA profiles in serum pools of MPM patients (N 
= 11), AD patients (N = 36), and healthy subjects (N = 45) to identify non-invasive bi-
omarkers for differential diagnosis of MPM and AD, using deep sequencing.  
Sequencing detected up to 300 known miRNAs and up to 25 novel miRNAs species in the se-
rum samples. Among known miRNAs, 7 were upregulated in MPM and 12 were upregulated 
in AD compared to healthy controls. Of these, eight were distinctive for AD and three were 
unique for MPM. Direct comparison of the miRNA profiles for MPM and AD revealed dif-
ferences in miRNA levels that could be useful for differential diagnosis. No differentially ex-
pressed novel miRNAs were found. Further bioinformatics analysis indicated that three up-
regulated miRNAs in MPM are associated with the p38 pathway. 
There are unique alterations in serum miRNAs in MPM and AD compared to healthy con-
trols, as well as differences between MPM and AD profiles. Differing miRNA levels between 
MPM and AD may be useful for differential diagnosis. A potential association to p38 path-
way of three upregulated miRNAs in MPM was revealed. 
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Malignant pleural mesothelioma (MPM) 
is an aggressive tumor arising from pleural 
mesothelial cells that is difficult to diagnose 
and unresponsive to conventional therapy 
(Bagheri et al., 2011). The gold standard di-
agnosis of MPM requires tissue sample anal-
ysis of tissue markers and relies on a panel 
of immunohistochemical stains since there is 
no single tissue marker with 100 % diagnos-
tic accuracy (Husain et al., 2009). This diag-
nostic process is not only difficult and time-
consuming, but also requires a tissue sample 
that must be obtained through an invasive 
procedure (Ray and Kindler, 2009). Due to 
the difficulty in obtaining an accurate patho-
logical diagnosis, final diagnoses include a 
combined analysis of clinical data, x-ray re-
sults, and pathology findings (Husain et al., 
2009). In addition, the most frequent subtype 
of MPM (epithelioid) can be difficult to dis-
tinguish from peripheral lung adenocarcino-
ma (AD). Distinguishing MPM from AD is 
clinically important since the two tumor 
types call for different treatment approaches. 
Recently, microRNAs (miRNAs) have 
been studied as potential diagnostic markers 
for MPM. MiRNAs are small non-coding 
RNAs that target mRNAs to regulate post-
transcriptional gene expression. They regu-
late many key cellular processes, including 
cell cycle progression, differentiation, prolif-
eration, apoptosis, and hematopoiesis 
(Carthew and Sontheimer, 2009). Notably, 
alterations in miRNA expression levels have 
been detected in solid tumors, distinguishing 
healthy tissue from tumor tissue (Avila-
Moreno et al., 2011). Nevertheless, to exam-
ine a miRNA profile for diagnostic purposes, 
tumor tissue has to be obtained through an 
invasive procedure. An alternative is to study 
miRNAs in blood circulation. Circulating, as 
opposed to local tissue, miRNAs have the 
potential to be used as non-invasive bi-
omarkers. Moreover, evidence indicates that 
miRNAs are secreted in a selective way as a 
component of cell-cell communication 
mechanisms and it has been hypothesized 
that cancer cells secrete miRNAs to affect 
their cellular environment (Pigati et al., 
2010; Wang et al., 2010). 
In the present study, we conducted a 
broad screening study of miRNA profiles in 
pooled serum samples from MPM patients 
(11), AD patients, and healthy control sub-
jects using deep sequencing. Our aim was to 
identify non-invasive biomarkers principally 
for the differential diagnosis of MPM and 
AD. This study included a gene and pathway 
enrichment analysis by bioinformatics to de-
termine the potential relevance of the differ-
entially expressed miRNAs to carcinogenesis 
mechanisms. Serum was chosen over plasma 
to avoid a bias related to miRNAs in plate-
lets (McDonald et al., 2011); and deep se-
quencing was used because it allows identi-
fication of all detectable known and novel 
miRNAs in blood circulation. 
 
MATERIAL AND METHODS 
Participants and samples 
Patients  
Patients with histological diagnosis of 
malignant pleural mesothelioma (MPM) sub-
type epithelioid, and No-Small Cell Lung 
Cancer (NSCLC) subtype adenocarcinoma 
(AD) with primary lung-origin, were recruit-
ed from the Pneumology-Oncology Service 
at the Instituto Nacional de Enfermedades 
Respiratorias (INER), Mexico City. The pa-
tients included in this study did not receive 
any adjuvant chemotherapy, surgery or ra-
diation therapy previous to the sample col-
lection. All patients were > 35 years old. The 
clinical data, smoking status and ancestry 
were obtained from clinical records and by 
personal inquiring guided by a standardized 
questionary. Exclusion criteria included a di-
agnosis of asthma, COPD, associated cancer, 
no primary lung-origin adenocarcinoma, 
HIV infection, or upper/lower respiratory 
tract infection in the preceding 4 weeks. 
MPM and AD diagnosis was confirmed 
by immunohistochemistry method by the Pa-
thology Department at INER. MPM im-
munohistochemistry diagnosis uses al least 
four of the next markers: calretinin, TTF-1 
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(thyroid transcription factor-1), citokeratin 
5/6, CEA (carcinoembryonic antigen), and 
BerEP4. Only samples with matching X-rays 
and clinical diagnosis of MPM were includ-
ed in this study. 
Healthy subjects 
Healthy subjects were recruited from an 
anti-smoking and blood donation campaign 
in the Instituto Nacional de Enfermedades 
Respiratorias (INER), Mexico City. All the 
subjects included in this study were born in 
Mexico as well as both parents and grand-
parents. None of the participants had airway 
obstruction (by determination of FEV1 
/FVC). All participants were > 35 years old. 
Exclusion criteria included a diagnosis of 
asthma, COPD, bronchiectasis, lung cancer, 
HIV infection, or upper/lower respiratory 
tract infection in the preceding 4 weeks.  
Written informed consent was obtained 
from all participants according to Scientific 
and Ethical Committee at the Instituto 
Nacional de Enfermedades Respiratorias 
(INER). 
Samples 
For the Solexa sequencing assay, equal 
volumes of sera from 23 healthy male smok-
ers (CTR-1), 22 healthy female smokers 
(CTR-2), 11 smokers and non-smokers 
MPM patients (MPM), 15 non-smokers AD 
patients (AD-1) and 21 smokers AD patients 
(AD-2), were pooled separately to complete 
a total volume of 4 ml per group sample for 
RNA extraction.  
 
Sample processing and RNA extraction 
Serum was obtained from peripheral 
blood samples (5-ml BD Vacutainer SST II 
Plus plastic serum Tube, REF 368159) by 
centrifugation at 4000 rpm at 4 °C for 20 
min. The serum was collected and stored at -
80 °C until analysis. Isolation of total RNA 
from serum pools was performed by a com-
bination of Trizol LS (Invitrogen) and miR-
Neasy kit (Qiagen) according to the manu-
facturer’s instructions. RNA profiles and 
quantification were assessed on the Agilent 
2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA) and the Small RNA chip. 
 
Deep sequencing by Solexa (Illumina) 
Small RNA library preparation and se-
quencing was performed at the Unidad de 
Secuenciación e Identificación de Poli-
morfismos at the Instituto Nacional de 
Medicina Genómica (INMEGEN), Mexico 
City. Briefly, total RNA (30 ng) was ligated 
to sequencing adaptors on both ends, and re-
verse-transcribed (TruSeq Small RNA Sam-
ple Prep Kit Set A, Illumina, Cat. RS-200-
0012). The resulting cDNA library was 
PCR-amplified for 15 cycles, concentrated 
by ethanol precipitation and gel-purified on 
6 % acrylamide gel. Fragments of 147 a 157 
nt (small RNA+adaptors) were isolated from 
the acrylamide gel and the quality of the pu-
rified DNA was checked using the chip 
DNA High Sensitivity (Agilent Technolo-
gies, Cat. 5067-4626) and the Agilent 2100 
Bioanalyzer. Purified DNA was used for 
cluster bridge generation (Bridge PCR con el 
kit TruSeq SR Cluster v5-CS-GS) by loading 
on to the Illumina cluster station (Illumina, 
Cat. GD-203-2001). The DNA clusters gen-
erated were sequenced using the Illumina’s 
Solexa Sequencer (Illumina, Cat. FC-104-
5020). Sequencing reads were generated and 
base calls were rendered using Illumina pipe-
line Version 1.3.2. 
 
Computational analysis procedure and 
pipeline 
Computational analysis of sequencing 
reads (.fastq files) was performed by the 
Winter Genomics Company (Winter Web In-
ternet and Network Technology for Enter-
prise Resources S.A. de C.V., Mexico City). 
Each sample went through two filtering pro-
cesses.  
The first process:  
a)  Filter by quality; reads with a median 
quality below 20 were removed.  
b)  Filter by Ns; reads with one or more N’s 
were removed.  
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c)  Filter by polynucleotides; reads harbor-
ing more than 60 % of the same base 
were removed.  
d)  Trimming of the small RNA 3’ adapter 
utilized to prepare the sequencing library.  
e)  Filter reads with a 15 base pair length or 
less.  
The second process:  
a)  minReadCount=numeric value: the min-
imum read count a read must have to be 
written to the output file. The numeric 
value chosen was 1 to increase the sensi-
bility of the miRanalyzer output.  
b)  Quality values: to control the quality of 
the reads, the mean quality score must be 
above a given threshold. The threshold 
value was 0.  
c)  maxLen = value: Reads with a length 
bigger than 26 bp were filtered. 
The identification of known and putative 
new miRNAs was performed by MiRanalyz-
er (Hackenberg et al. 2009, 2011), which de-
tects known miRNAs and predicts new puta-
tive miRNAs following the next criteria:  
a)  Filtering of the reads that aligned to 
RepBase (Jurka, 2000).  
b)  Identification of all reads that came from 
other small non-coding RNAs by align-
ing the filtered reads against Rfam 
(Gardner et al., 2011).  
c)  Detection of known miRNAs by map-
ping the remaining reads against miR-
Base (Kozomara and Griffiths-Jones, 
2011).  
d)  Prediction of new putative miRNAs 
based on a learning machine approach 
based on a  random forest method.  
 
Differential expression 
The statistical significance of differences 
in miRNAs level expression was calculated 
using the miRanalyzer tool ’Differential ex-
pression analysis’ which performs a variance 
analysis using the Bioconductor package 
DESeq (Hackenberg et al., 2011). For every 
comparison requested, differential expres-
sion was tested for unique known miRNAs, 
unique unobserved miRNAs and novel 
miRNAs. In order to determine differential 
expression of a miRNA species in the analy-
sis a cutoff value of expression fold-change 
of log2  > 2 between the samples involved at 
each analysis was used and a p-value of 
< 0.01. 
 
Gene set enrichment analysis  
Gene and pathway enrichment analyses were 
performed using the miRSystem, an Integrated 
System for Characterizing Enriched Functions 
and Pathways of MicroRNA Targets (Lu et al., 
2012) (http://miRSystem.cgm.ntu.edu.tw/). Us-
ing this system, queried miRNAs are first 
converted to the latest miRBase annotation, 
then several statistical methods are applied to 
calculate O/E ratios of gene targets, hyper-
geometric P-values, and empirical P-values 
due to permutation in order to identify sig-
nificantly enriched signaling pathways. 
MiRSystem includes seven algorithms pre-
dicting miRNA targets: DIANA-microT, 
miRanda, mirBridge, PicTar, PITA, rna22, 
and TargetScan, and two experimentally val-
idated databases, TarBase and miRecords of 
miRNA target genes were included. Five 
pathway databases, including Gene Onto-
logy, KEGG, BioCarta, Pathway Interaction 
Database, and Reactome, were used to anno-
tate the biological functions and canonical 
pathways of target genes. 
 
RESULTS 
Characteristics of the study population 
Table 1 shows the distributions of demo-
graphic and clinical features in the study 
groups. All MPM patients presented with 
pleural effusion. The AD group was subdi-
vided based on whether individuals were 
non-smokers or smokers into adenocarcino-
ma groups 1 (AD-1) and 2 (AD-2), respec-
tively. None of the cancer patients had asso-
ciated infectious respiratory diseases, associ-
ated neoplasias or received adjuvant chemo-
therapy, surgery or radiation therapy prior to 
sample collection. The control subjects were 
all smokers and were subdivided into male 
(CTR-1) and female (CTR-2) groups. None 
of the controls had hypertension, diabetes, or 
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respiratory diseases, such as asthma and 
chronic obstructive pulmonary disease. 
 
Identification of miRNAs in serum  
A preliminary wide screen of miRNA 
profiles in serum pools from 11 MPM sub-
jects, 36 AD (AD-1 and AD-2) subjects, and 
45 healthy controls (CTR-1 and CTR-2) by 
deep sequencing generated ~6 million raw 
reads for each serum pool sample (Figure 1) 
and detected ~300 unique known miRNAs 
and up to 25 novel miRNAs in all of the 
samples. 
 
Differential expression of serum miRNAs 
in lung cancer patients 
Among the known miRNAs detected, 7 
were found to be upregulated in MPM serum 
samples and 12 were upregulated in AD se-
rum samples, compared to controls (Table 
2). There were no differentially expressed 
novel miRNAs in the AD and MPM groups 
compared to normal controls. Examination 
of the distribution of the deregulated miR-
NAs revealed that four of them were shared 
by both neoplasias (hsa-miR-4791, hsa-miR-
185-5p, hsa-miR-96-5p, and hsa-miR-1271-
5p), suggesting a common link between lung 
and pleural neoplasias (Figure 2). Three 
miRNAs were unique to the MPM patients 
(hsa-miR-1292-5p, has-miR-409-5p, and 
has-miR-92b-5p), and eight miRNAs were 
unique to the AD patients (hsa-miR-1246, 
hsa-miR-1290, hsa-miR-4488, hsa-miR-19a-
3p, hsa-miR-200b-3p, hsa-miR-429, hsa-
miR-141-3p, and hsa-miR-1299). 
A direct comparison of miRNA levels 
between the two neoplasias (by miRanalyzer 
tool Differential expression analysis) showed 
13 upregulated miRNAs (hsa-miR-1292-5p, 
hsa-140-5p, hsa-miR-184, hsa-miR-1908, 
hsa-miR-23b-5p, has-miR-3198, hsa-miR-
323b-3p, hsa-miR-331-3p, hsa-miR-409-5p,   
 
 
Table 1: Demographic and clinical features of mesothelioma patients, lung cancer patients and 
healthy subjects 
 Patients Healthy subjects 
 MPM AD-1 AD-2 CTR-1 CTR-2 
# Subject 11 15 21 23 22 
Gender (# subjects) M (10) / F (1) M (4) / F (11) M (13) / F (8) M F 
Average age (years) 65.8 + 13.4 61.7 + 11.4 60.9 + 15.4 47.25 + 5.8 57.0 + 10.0 
Smoking (# subjects) Yes (9) / No (2) No Yes Yes Yes 
# of cigarettes/day 12.8 + 8.3 - 8.3 + 12.4 23.0 + 6.7 20.3 + 2.2 
# Subject with: 
Wood smoke exposure 4 9 10 0 0 
Hypertension 4 8 4 ND ND 
Diabetes 1 4 5 0 0 
Cardiac disease 2 0 1 0 0 
Asthma 0 0 0 0 0 
COPD 0 0 0 0 0 
Pleural effusion 11 9 6 0 0 
Histologic diagnosis epithelioid MPM AD AD - - 
Stage (# subjects) IIIA (1) / IIIB (3) / 
IV (4) / IIA (1) / 
no reported (3) 
IIIB (4) / IV (17) IIIB (1) / IV (14) - - 
AD: lung adenocarcinoma, MPM: malignant pleural mesothelioma, CTR: healthy control, COPD: Chronic Obstructive Pulmonary 
Disease. ND: no determined. (  ): Number of subjects 
EXCLI Journal 2014;13:740-750 – ISSN 1611-2156 




Figure 1: Numbers of miRNAs reads found in serum sample pools by deep sequencing 
 
 
Table 2: Differentially expressed miRNAs in pooled serum samples from MPM patients and from AD  
patients compared to healthy controls 
miRNA 
MPM vs CTRs 
Pval Log2Fold Change 
hsa-miR-4791 0.00002 8.93 
hsa-miR-185-5p 0.0017 3.995 
hsa-miR-96-5p 0.0048 4.453 
hsa-miR-1271-5p 0.00399 Inf 
hsa-miR-1292-5p 0.00123 Inf 
hsa-miR-409-5p 0.00747 Inf 
hsa-miR-92b-5p 0.001 6.33 
miRNA 
ADs vs CTRs 
Pval Log2Fold Change 
hsa-miR-1246 0.00744 3.1965 
hsa-miR-1290 0.00021 7.327 
hsa-miR-4791 0.00029 10.1449 
hsa-miR-4488 0.00827 Inf 
hsa-miR-19a-3p 0.0044 5.546 
hsa-miR-200b-3p 0.00339 5.4731 
hsa-miR-429 0.00083 Inf 
hsa-miR-96-5p 0.00049 5.2913 
hsa-miR-141-3p 0.00044 5.1956 
hsa-miR-1299 0.00855 5.0832 
hsa-miR-185-5p 0.00471 5.1217 
hsa-miR-1271-5p 0.00113 Inf 




505-5p, hsa-miR-5706), and 5 down-
regulated miRNAs (hsa-miR-106a-5p, hsa-
miR-200b-3p, hsa-miR-216b, hsa-miR-23c, 
hsa-miR-29b-3p) in MPM compared to AD 
(Table 3). Notably, hsa-miR-1292-5p and 
hsa-miR-409-5p were upregulated in MPM 
versus AD as well in MPM compared to 
healthy controls (Figure 2). 
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Figure 2: Distributions of the deregulated  
miRNAs in MPM and AD samples  
  
Biological relevance of differentially  
expressed miRNAs 
A gene and pathway enrichment analysis 
conducted with MiRSystem identified 1,115 
genes as predicted targets of the seven miR-
NAs upregulated in MPM compared to nor-
mal controls. As shown in Table 4, an analy-
sis of the biological pathways in which these 
target genes participate revealed that the 
p38-signaling pathway, regulation of p38-
alpha and P30-beta pathways, and gluconeo-
genesis were the top three (most significant-
ly) enriched pathways (p ≤ 0.01).  
Further analysis of the p38 pathway 
showed that three of the seven upregulated 
miRNAs in MPM (hsa-miR-96-5p, hsa-miR-
1271, and hsa-miR-409-5p) targeted genes in 
p38-related pathways, namely MAP2K3, 
FYN, and MAP2K10 (Figure 3). In addition, 
we found two more enriched pathways 
(p ≤ 0.05) in the top 15 positions that were 
related to the three top pathways mentioned 
above: the signaling events mediated by 
VEGFR1 and VEGFR2 (raw p = 1.53E-02) 
and the Biocarta MAPK pathway (raw p = 
2.38E-02) (Figure 3, grey font); and target 
genes were common to the previous three 






Table 3: Differentially expressed miRNAs in serum MPM patients compared to AD patients 
miRNA 
MPM vs ADs 
Pval Log2Fold Change 
Upregulated in MPM   
hsa-miR-1292-5p 0 2.345 
hsa-miR-140-5p 0 2.5906 
hsa-miR-184 0 3.1029 
hsa-miR-1908 0 2.1333 
hsa-miR-23b-5p 0 6.6256 
hsa-miR-3198 0.00944 Inf 
hsa-miR-323b-3p 0.00012 2.868 
hsa-miR-331-3p 0.00024 2.7019 
hsa-miR-409-5p 0.00012 2.603 
hsa-miR-4683 0.001 4.859 
hsa-miR-4707-3p 8.00E-04 2.7398 
hsa-miR-505-5p 3.00E-05 3.1857 
hsa-miR-5706 0.00685 4.5701 
Downregulated in MPM   
hsa-miR-106a-5p 0.00233 -2.5094 
hsa-miR-200b-3p 0 -Inf 
hsa-miR-216b 0.00152 -Inf 
hsa-miR-23c 0 -2.5137 
hsa-miR-29b-3p 0.01025 -3.4676 
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Table 4: Top three enriched pathways of miRNAs differentially expressed in MPM patients sera com-
pared to normal controls 
Group of miRNAs  
analyzed Database Pathway 







7 upregulated miRNAs 
MPM vs CTR 
Pathway interaction 
database 
p38 MAPK signaling 
pathway 2 3 3.04E-03 
Pathway interaction 
database 
Regulation of p38-alpha 
and p38-beta 2 2 3.46E-03 
Reactome Gluconeogenesis 2 2 3.46E-03 
The predictive target genes of the deregulated miRNAs in MPM were analyzed by miRSystem to find the top 3 pathways 
(p<0.01) where they are enriched. ** Raw P-values were obtained by a hypergeometric test. 
 
 




In the present study, a wide screen of se-
rum miRNAs identified distinctive miRNA 
profiles between MPM and AD patients. In 
particular, hsa-miR-1292-5p and hsa-miR-
409-5p were upregulated in MPM versus AD 
as well in MPM compared to healthy con-
trols, implicating these two miRNAs strong-
ly as potential biomarkers for differentiating 
MPM from AD. In addition, the biological 
pathways in which the identified differenti-
ated miRNAs’ target genes participate (hsa-
miR-1271, hsa-miR-96-5p and hsa-miR-409) 
include most predominantly the p38 signal-
ing pathway, regulation of p38-alpha and 
p30-beta pathways, and gluconeogenesis.  
The p38 signaling pathway activates mi-
togen-activated protein (MAP) kinases asso-
ciated with regulation of apoptosis, the cell 
cycle, and inflammation. Activation of p38 
has been reported to be reduced in tumors, 
and this reduction may contribute to in-
creased proliferation and increased likeli-
hood of tumorigenic conversion (Brancho et 
al., 2003; Zarubin and Han, 2005). Glucone-
ogenesis seems not to be directly related to 
tumor development, but it could be associat-
ed with survival in low-nutrient environ-
ments.  
There are two particularly interesting 
genes targeted by the miRNAs that were 
found to be upregulated in MPM. The first, 
MAP2K3, is an upstream activator of p38. 
Indeed there is evidence suggesting that 
MAP2K3 is the major determinant of p38 
MAPK activation and it may need to be ac-
tive for tumor growth suppression (Galan-
Moya et al., 2011; Zhu et al., 2011; MacNeil 
EXCLI Journal 2014;13:740-750 – ISSN 1611-2156 
Received: May 01, 2014, accepted: May 27, 2014, published: July 08, 2014  
 
748 
et al., 2014). Although studies have reported 
that the biological consequences of p38 acti-
vation depend on cell type and the stimulus 
applied (Brancho et al., 2003; Zarubin and 
Han, 2005), activation of p38 by upregulated 
MAP2K3 may be necessary for suppression 
of tumor growth (i.e. breast cancer, glioblas-
toma, non-small cell lung cancer [NSCLC]) 
(Galan-Moya et al., 2011; Zhu et al., 2011; 
MacNeil et al., 2014). Hence, tumorigenesis 
could become more likely when p38 activity 
has been reduced by upregulated and secret-
ed miRNAs from neighboring tumor cells, 
indicating a potential biological relevance of 
hsa-miR-1271, hsa-miR-96-5p and hsa-miR-
409 in tumorigenesis and as potential circu-
lating biomarkers of MPM. 
Use of circulating, rather than local tis-
sue, miRNAs as biomarkers has noteworthy 
advantages. Firstly, drawing blood is rela-
tively non-invasive, especially relative to 
lung and pleural tissue biopsies. In addition, 
serum can be used rather plasma to avoid 
distortion of findings related to miRNAs in 
platelets (McDonald et al., 2011). A wide 
screen of circulating miRNAs was per-
formed in this study because secreted miR-
NA profiles have been reported to differ 
from tissue miRNA profiles (Ohshima et al., 
2010; Pigati et al., 2010); indeed new miR-
NAs have been discovered in circulation 
(Chen et al., 2008).  
To our knowledge, this is the first report 
of differential miRNA profiles in sera from 
MPM and AD patients. This is also the first 
report of a wide screen for miRNAs in serum 
from patients with MPM. Kirschner et al. 
(2012) reported increased circulating miR-
625-3p as a potential biomarker for MPM in 
plasma and serum; however, they performed 
their first screening in plasma samples, and 
then examined levels of only hsa-miR-625-
3p in serum and plasma samples. Their re-
sults did not match our data, perhaps because 
plasma samples contain cellular miRNAs 
from platelets that could mask cell-freel 
miRNAs in circulation.  
On the other hand, our AD serum miR-
NA data differ from the data reported by 
Roth et al. (2012), who performed serum-
based miRNA profiling of 1158 known 
miRNAs using microfluid biochips. They re-
ported finding 30 deregulated miRNAs in 
NSCLC, but did not mention if a differential 
analysis had been performed for the different 
subtypes of NSCLC analyzed. Chen et al. 
(2012) identified ten serum miRNAs as bi-
omarkers for NSCLC patients. Those miR-
NAs differed from the miRNAs identified in 
the present study, perhaps because they ana-
lyzed only deregulated miRNAs identified in 
a previous study that did not include a differ-
ential analysis between NSCLC subtypes. 
Not analyzing NSCLC subtypes separately 
might obscure differences in levels of partic-
ular miRNAs. Studies of tissue miRNAs 
have showed miRNA profile differences be-
tween AD and squamous cell carcinoma that 
are were not found when they were analyzed 
as a broad group of NSCLC samples 
(Lebanony et al., 2009; Landi et al., 2010). 
In conclusion, our findings indicate that 
serum miRNA profiles may be a suitable 
non-invasive tool for distinguishing between 
MPM and AD, either through comparison to 
healthy controls or by comparison between 
the two neoplasias. These data point to at 
least three miRNAs as potential diagnostic 
biomarkers for MPM - namely hsa-miR-
1271, has-miR-96-5p, and hsa-miR-409 -  
due to their potential association with car-
cinogenesis mechanisms, and - hsa-miR-
1292-5p and hsa-miR-409-5p - due to their 
upregulation in MPM though both compari-
sons. Our results need to be verified by a 
quantitative method, such real-time poly-
merase chain reaction, and in experiments 
using individual serum samples. 
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